Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis-Reference-Cited by-同舟云学术

Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis

Published:2014-06 Issue:3 Volume:14 Page:245-251
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

DeAngelo Daniel J.,Chen Lei,Guerin Annie,Styles Amy,Giguere-Duval Philippe,Wu Eric Q.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference16 articles.

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

2. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience;Kantarjian;Blood,2012

3. Overriding imatinib resistance with a novel ABL kinase inhibitor;Shah;Science,2004

4. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia;Hughes;N Engl J Med,2003

5. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial;Kantarjian;Blood,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2020-02

2. A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant;Bioorganic & Medicinal Chemistry Letters;2016-08

3. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question;Critical Reviews in Oncology/Hematology;2016-07

4. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes;British Journal of Haematology;2016-02-05